Hansa Biopharma interim report Jan-Mar 2021 |
| April 22, 2021 | April 2021 Bond Updates |
|
LUND, Sweden, April 22, 2021 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January – March, 2021. Highlights for the first quarter 2021 First commercial sales of... |
| View more at: https://www.prnewswire.com:443/news-releases/hansa-biopharma-interim-report-jan-mar-2021-301274522.html |
| Related News |
|